United Therapeutics scores FDA go-ahead for pig organ transplant clinical trial
Silver Spring’s United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to be transplanted into humans. It's as significant for the medical community as it is for the business.
The second person ever has received a transplant with a genetically modified pig kidney.
Mass General Brigham has announced the successful completion of another gene-edited pig kidney transplant, the first of a ...
Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...
United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...
UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback